Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination

References

• Cohn A, MacNeil J. The changing epidemiology of meningococcal disease. Infect Dis Clin North Am. 2015;29(4):667–677. doi:10.1016/j.idc.2015.08.002.
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–2210. doi:10.1016/S0140-6736(07)61016-2.
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013; 11(1):11–17.doi:10.1186/1478-7954-11-17.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31(1):101–107. doi:10.1111/j.1574-6976.2006.00053.x.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease. [ accessed 2018 Jun 12]. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf.
   Google Scholar
• Environmental Health Indicators New Zealand. Notifications of meningococcal disease. [accessed 2017 Oct 2]. http://www.ehinz.ac.nz/assets/Factsheets/Released-2015/EHI72-NotificationsOfMeningococcalDiseaseInNZ1997-2014-released201508.pdf.
   Google Scholar
• Mounchetrou Njoya I, Deghmane A, Taha M, Isnard H, Du Chatelet IP. A cluster of meningococcal disease caused by rifampicin-resistant C meningococci in France, April 2012. Euro Surveill. 2012;17(34). pii: 20254
   PubMedGoogle Scholar
• Hoebe CJ, de Melker H, Spanjaard L, Dankert J, Nagelkerke N. Space-time cluster analysis of invasive meningococcal disease. Emerg Infect Dis. 2004;10(9):1621–1626. doi:10.3201/eid1009.030992.
   PubMed Web of Science ®Google Scholar
• Le Guerrier P, Pilon P, Sauvageau C, Deshaies D. Spatio-temporal cluster of cases of invasive group B Neisseria meningitidis infections on the island of Montreal. Can Commun Dis Rep. 1997;23(4):25–28.
   PubMedGoogle Scholar
• Jelfs J, Jalaludin B, Munro R, Patel M, Kerr M, Daley D, Neville S, Capon A. A cluster of meningococcal disease in western Sydney, Australia initially associated with a nightclub. Epidemiol Infect. 1998;120(3):263–270.
   PubMed Web of Science ®Google Scholar
• Maoldomhnaigh CO, Drew RJ, Gavin P, Cafferkey M, Butler KM. Invasive meningococcal disease in children in Ireland, 2001-2011. Arch Dis Child. 2016;101(12):1125–1129. doi:10.1136/archdischild-2015-310215.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E, Ramsay ME, Borrow R. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–585. doi:10.1093/cid/ciu881.
   PubMed Web of Science ®Google Scholar
• Soeters HM, McNamara LA, Whaley M, Wang X, Alexander-Scott N, Kanadanian KV, Kelleher CM, MacNeil J, Martin SW, Raines N, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college - Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606–607.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Disease data from ECDC Surveillance Atlas for meningococcal disease. [accessed 2018 Jun 25]. https://ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/atlas.
   Google Scholar
• Read RC. Neisseria meningitidis; clones, carriage, and disease. Clin Microbiol Infect. 2014;20(5):391–395. doi:10.1111/1469-0691.12647.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–861. doi:10.1016/S1473-3099(10)70251-6.
   PubMed Web of Science ®Google Scholar
• Vetter V, Baxter R, Denizer G, Safadi MA, Silfverdal SA, Vyse A, Borrow R. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15(5):641–658. doi:10.1586/14760584.2016.1130628.
   PubMed Web of Science ®Google Scholar
• International Monetary Fund. World economic outlook: Cyclical upswing, structural change. Washington (DC): International Monetary Fund; 2018.
   Google Scholar
• Soriano-Gabarro M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther. 2011;9(9):761–774. doi:10.1586/eri.11.89.
   PubMed Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, Evans MR, Cann K, Baxter DN, Maiden MC, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12(6):950–957. doi:10.3201/eid1206.051297.3201/eid1206.051297.3201/eid1206.051297.3201/eid1206.051297.
   PubMed Web of Science ®Google Scholar
• Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688–693.
   PubMed Web of Science ®Google Scholar
• Neal KR, Nguyen-Van-Tam JS, Jeffrey N, Slack RC, Madeley RJ, Ait-Tahar K, Job K, Wale MC, Ala’Aldeen DA. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ. 2000;320(7238):846–849.
   PubMed Web of Science ®Google Scholar
• Palmgren H. Meningococcal disease and climate. Glob Health Action. 2009;2. doi:10.3402/gha.v2i0.2061
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MC. Meningococcal carriage and disease–population biology and evolution. Vaccine. 2009;27(suppl 2):B64–70. doi:10.1016/j.vaccine.2009.04.061.
   PubMed Web of Science ®Google Scholar
• Steffen R. The risk of meningococcal disease in travelers and current recommendations for prevention. J Travel Med. 2010;17(suppl):9–17. doi:10.1111/j.1708-8305.2010.00449.x.
   PubMed Web of Science ®Google Scholar
• Heywood AE, Zhang M, MacIntyre CR, Seale H. Travel risk behaviours and uptake of pre-travel health preventions by university students in Australia. BMC Infect Dis. 2012;12:43. doi:10.1186/1471-2334-12-43.
   PubMed Web of Science ®Google Scholar
• Bosis S, Mayer A, Esposito S. Meningococcal disease in childhood: epidemiology, clinical features and prevention. J Prev Med Hyg. 2015;56(3):E121–124.
   PubMedGoogle Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(suppl 2):B3–B9. doi:10.1016/j.vaccine.2011.12.062.
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403. doi:10.1016/S0140-6736(06)67932-4.
   PubMed Web of Science ®Google Scholar
• Campbell H, Parikh SR, Borrow R, Kaczmarski E, Ramsay ME, Ladhani SN. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill. 2016;21(12). doi:10.2807/1560-7917.ES.2016.21.12.30175.
   Google Scholar
• Australian Government Department of Health. Invasive meningococcal disease national surveillance report with a focus on MenW. [ accessed 2018 Mar 5]. https://www.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/Sept-2017-IMD-Surveillance-report.pdf.
   Google Scholar
• Vaccine preventable disease. Surveillance report to December 31, 2015. Ottowa, ON, Canada: Public Health Agency of Canada; 2017.
   Google Scholar
• The Institute of Environmental Science and Research Ltd. Notifiable diseases in New Zealand: Annual report. 2016. [ accessed 2018 Apr 25]. https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2016/2016AnnualNDReportFinal.pdf.
   Google Scholar
• Enhanced meningococcal disease surveillance report, 2016. Hyattsville, MD: Centers for Disease Control and Prevention; 2017.
   Google Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years–United States. 2016. [ accessed 2016 Nov 30]. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf.
   Google Scholar
• Lopez L, Sherwood J, Institute of Environmental Science and Research. The epidemiology of meningococcal disease in New Zealand in 2013. [ accessed 2018 Mar 14]. https://surv.esr.cri.nz/PDF_surveillance/MeningococcalDisease/2013/2013AnnualRpt.pdf.
   Google Scholar
• Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26(5):1159–1164.
   PubMed Web of Science ®Google Scholar
• Archer BN, Chiu CK, Jayasinghe SH, Richmond PC, McVernon J, Lahra MM, Andrews RM, McIntyre PB. Australian technical advisory group on immunisation meningococcal working P. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination. Med J Aust. 2017;207(9):382–387.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease: Diagnosis, treatment, and complications. [ accessed 2017 Nov 29]. https://www.cdc.gov/meningococcal/about/diagnosis-treatment.html.
   Google Scholar
• Meningitis Research Foundation. After effects. [ accessed 2017 Mar 17]. http://www.meningitis.org/disease-info/after-effects.
   Google Scholar
• Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502–e509. doi:10.1542/peds.2008-0581.
   PubMed Web of Science ®Google Scholar
• Brooks R, Woods CW, Benjamin DK Jr., Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis. 2006;43(1):49–54. doi:10.1086/504804.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Centers for disease C, prevention. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2013;62(RR–2):1–28.
   PubMed Web of Science ®Google Scholar
• Smith-Palmer A, Oates K, Webster D, Taylor S, Scott KJ, Smith G, Parcell B, Lindstrand A, Wallensten A, Fredlund H, et al. Outbreak of Neisseria meningitidis capsular group W among scouts returning from the World Scout Jamboree, Japan, 2015. Euro Surveill. 2016;21(45). doi:10.2807/1560-7917.ES.2016.21.45.30392.
   Google Scholar
• Public Health Agency of Canada. Notifiable disease charts. [ accessed 2018 Jun 25]. http://dsol-smed.phac-aspc.gc.ca/notifiable/charts-list.
   Google Scholar
• Australian Government Department of Health. National notifiable diseases surveillance system. Notification rate of meningococcal disease (invasive)*, Australia, 2018 by age group and sex. [ accessed 2018 Jun 28]. http://www9.health.gov.au/cda/source/rpt_5.cfm.
   Google Scholar
• Atkinson B, Gandhi A, Balmer P. History of meningococcal outbreaks in the United States: implications for vaccination and disease prevention. Pharmacotherapy. 2016;36(8):880–892. doi:10.1002/phar.1790.
   PubMed Web of Science ®Google Scholar
• Chatt C, Gajraj R, Hawker J, Neal K, Tahir M, Lawrence M, Gray SJ, Lucidarme J, Carr AD, Clark SA, et al. Four-month outbreak of invasive meningococcal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping, England, 2013. Euro Surveill. 2014;19(44). doi:10.2807/1560-7917.ES2014.19.44.20949.
   PubMedGoogle Scholar
• Stewart A, Coetzee N, Knapper E, Rajanaidu S, Iqbal Z, Duggal H. Public health action and mass chemoprophylaxis in response to a small meningococcal infection outbreak at a nursery in the West Midlands, England. Perspect Public Health. 2013;133(2):104–109. doi:10.1177/1757913912439928.
   PubMed Web of Science ®Google Scholar
• Tzanakaki G, Kesanopoulos K, Yazdankhah SP, Levidiotou S, Kremastinou J, Caugant DA. Conventional and molecular investigation of meningococcal isolates in relation to two outbreaks in the area of Athens, Greece. Clin Microbiol Infect. 2006;12(10):1024–1026. doi:10.1111/j.1469-0691.2006.01521.x.
   PubMed Web of Science ®Google Scholar
• Acheson P, Barron R, Borrow R, Gray S, Marodi C, Ramsay M, Waller J, Flood T. A cluster of four cases of meningococcal disease in a single nuclear family. Arch Dis Child. 2012;97(3):248–249. doi:10.1136/archdischild-2011-301074.
   PubMed Web of Science ®Google Scholar
• National Institute for Public Health and the Environment: Ministry of Health WaS. Meningococcal disease in the Netherlands: Background information for the Health Council. [ accessed 2018 Mar 5]. https://www.rivm.nl/dsresource?objectid=bc885ef5-793e-49e9-a275-18483989d62b&type=pdf&disposition=inline.
   Google Scholar
• Knol MJ, Hahne SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2(10):e473–e482. doi:10.1016/S2468-2667(17)30157-3.
   PubMed Web of Science ®Google Scholar
• Santé Publique France. Les infections invasives à méningocoques en 2016. Centre National de Référence des méningocoques, Institut Pasteur. [ accessed 2018 Apr 10]. http://invs.santepubliquefrance.fr/content/download/140827/509158/version/3/file/BilanIIM2016.pdf.
   Google Scholar
• Bassi C, Taha MK, Merle C, Hong E, Levy-Bruhl D, Barret AS, Mounchetrou Njoya I. A cluster of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup W among university students, France, February to May 2017. Euro Surveill. 2017;22(28). doi:10.2807/1560-7917.ES.2017.22.28.30574.
   PubMedGoogle Scholar
• Abad R, Medina V, Stella M, Boccadifuoco G, Comanducci M, Bambini S, Muzzi A, Vázquez JA. Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries. PLoS One. 2016;11(3):e0150721. doi:10.1371/journal.pone.0150721.
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Scott KJ, Ure R, Smith A, Lindsay D, Stenmark B, Jacobsson S, Fredlund H, Cameron JC, Smith-Palmer A, et al. An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016;21(45). pii: 30395. doi:10.2807/1560-7917.ES.2016.21.45.30395.
   Google Scholar
• Australian Government Department of Health. Australian meningococcal surveillance programme annual report. 2015. 40. http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-menganrep.htm.
   Google Scholar
• Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282(8):417–420. doi:10.1056/NEJM197002192820803.
   PubMed Web of Science ®Google Scholar
• Immunization Action Coalition. Meningococcal: questions and answers. Information about the disease and vaccines. [ accessed 2017 Nov 29]. http://www.immunize.org/catg.d/p4210.pdf.
   Google Scholar
• Holst J, Oster P, Arnold R, Tatley MV, Naess LM, Aaberge IS, Galloway Y, McNicholas A, O’Hallahan J, Rosenqvist E, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–1253. doi:10.4161/hv.24129.
   PubMed Web of Science ®Google Scholar
• Artenstein AW, LaForce FM. Critical episodes in the understanding and control of epidemic meningococcal meningitis. Vaccine. 2012;30(31):4701–4707. doi:10.1016/j.vaccine.2012.04.024.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Sullivan E. Meningococcal vaccinations. Infect Dis Ther. 2016;5(2):89–112. doi:10.1007/s40121-016-0107-0.
   PubMed Web of Science ®Google Scholar
• Prymula R, Szenborn L, Silfverdal SA, Wysocki J, Albrecht P, Traskine M, Gardev A, Song Y, Borys D. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants. Vaccine. 2017;35(35Pt B):603–4611. doi:10.1016/j.vaccine.2017.07.008.
   Web of Science ®Google Scholar
• Ministerio de Salud (Republica Argentina). Calendario Nacional de Vacunación 2017. [ accessed 2018 Mar 14]. http://www.msal.gob.ar/index.php/programas-y-planes/184-calendario-nacional-de-vacunacion-2016.
   Google Scholar
• Menveo (Meningococcal Group A, C, W135 and Y conjugate vaccine). Summary of product characteristics. Sovicille (Italy): GSK Vaccines S.r.l.; 2014.
   Google Scholar
• Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). Full prescribing information. Sovicille (Italy): Gsk Vaccines, Srl; 2017.
   Google Scholar
• Menactra (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine). Full prescribing information. Toronto (Ontario, Canada): Sanofi Pasteur Limited; 2017.
   Google Scholar
• Menactra (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine). Full prescribing information. Macquarie Park (NSW, Australia): Sanofi-Aventis Australia Pty Ltd; 2018.
   Google Scholar
• Menactra (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine). Full prescribing information. Auckland (New Zealand): Sanofi-Aventis New Zealand Pty Ltd; 2015.
   Google Scholar
• Menactra (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection). Full prescribing information. Swiftwater (PA): Sanofi Pasteur Inc; 2018.
   Google Scholar
• Nimenrix (Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Full prescribing information. West Ryde (NSW, Australia): Prizer Australia Pty Ltd; 2017.
   Google Scholar
• Nimenrix (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine). Full prescribing information. Auckland (New Zealand): Pfizer New Zealand Limited; 2018.
   Google Scholar
• NIMENRIX (meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Summary of product characteristics. Sandwich (Kent, UK): Pfizer Limited; 2017.
   Google Scholar
• Bexsero (MenB-4C). Full prescribing information. Abbotsford (Victoria, Australia): GlaxoSmithKline Australia Pty Ltd; 2017.
   Google Scholar
• Bexsero (MenB-4C). Mississauga (Ontario, Canada): GlaxoSmithKline Inc; 2017.
   Google Scholar
• Bexsero® (4CMenB). Summary of product characteristics. Uxbridge (Middlesex, UK): GlaxoSmithKline; 2017.
   Google Scholar
• Bexsero (Meningococcal Group B Vaccine). Full prescribing information. Sovicille (SI) (Italy): GSK Vaccines, Srl; 2018.
   Google Scholar
• Trumenba full prescribing information. West Ryde (NSW, Australia): Pfizer Australia Pty Ltd; 2017.
   Google Scholar
• Trumenba (Meningococcal group B vaccine [Bivalent recombinant lipoprotein (rLP2086)]). Full prescribing information. Kirkland (Quebec, Canada): Pfizer Canada Ltd; 2018.
   Google Scholar
• Trumenba (MenB-FHbp). Summary of product characteristics. Sandwich (UK): Pfizer Ltd; 2017.
   Google Scholar
• Trumenba (Meningococcal Group B Vaccine). Full prescribing information. Philadelphia (PA): Pfizer Inc; 2018.
   Google Scholar
• Menjugate (Meningococcal Group C–CRM197 Conjugate Vaccine). Full prescribing information. Mississauga (Ontario, Canada): GlaxoSmithKline Inc; 2017.
   Google Scholar
• NEISVAC-C (Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate)). Full prescribing information. Auckland (New Zealand): Pfizer New Zealand Limited; 2015.
   Google Scholar
• NeisVac-C Vaccine (Meningococcal Group C-TT Conjugate Vaccine, Adsorbed). Full prescribing information. Kirkland (Quebec, Canada): Pfizer Canada Ltd; 2015.
   Google Scholar
• Menitorix (Haemophilus influenzae type b polyribose ribitol phosphate and serogroup C meningococcal polysaccharide conjugate vaccine (Hib-MenC)). Full prescribing information. Abbotsford (Victoria, Australia): GlaxoSmithKline Australia Pty Ltd; 2016.
   Google Scholar
• New Zealand Ministry of Health. Meningococcal B immunisation programme and MeNZB™ vaccine. [ accessed 2018 Jun 29]. https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/immunisation-programme-decisions/meningococcal-b-immunisation-programme-and-menzbtm-vaccine.
   Google Scholar
• Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015-2016. Emerg Infect Dis. 2017;23(7):1184–1187. doi:10.3201/eid2307.170236.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743. doi:10.1086/527401.
   PubMed Web of Science ®Google Scholar
• Haut Conseil de la Santé Publique. Meningococcal vaccine C. [ accessed 2017 Aug 17]. http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=593.
   Google Scholar
• World Health Organization. WHO recommendations for routine immunization - summary tables (Table 1). [ accessed 2017 Apr 28]. http://www.who.int/immunization/policy/immunization_tables/en/.
   Google Scholar
• The Australian immunisation handbook. 10th edition. Canberra, Australia: Australian Government Department of Health; 2017.
   Google Scholar
• Government of Canada. Canadian Immunization Guide: Part 4 -Active Vaccines. [ accessed 2018 Jul 1]. https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for meningococcal disease. [ accessed 2017 Jul 20]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• Immunisation handbook 2017. 2nd edition. Wellington, New Zealand: New Zealand Ministry of Health; 2018.
   Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–1176. doi:10.15585/mmwr.mm6441a3.
   PubMed Web of Science ®Google Scholar
• Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine — advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509–513. doi:10.15585/mmwr.mm6619a6.
   PubMed Web of Science ®Google Scholar
• Ali A, Jafri RZ, Messonnier N, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health. 2014;108(1):11–20. doi:10.1179/2047773214Y.0000000126.
   PubMed Web of Science ®Google Scholar
• Li YA, Tsang R, Desai S, Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Can Commun Dis Rep. 2014;40(9):160–169.
   PubMedGoogle Scholar
• BC Centre for Disease Control. HealthLinkBC. Meningococcal quadrivalent vaccines. Number 23b. [ accessed 2017 Oct 3]. https://www.healthlinkbc.ca/healthlinkbc-files/meningococcal-quadrivalent-vaccines.
   Google Scholar
• Alberta Health. Routine immunization schedule. [ accessed 2017 Oct 3]. www.health.alberta.ca/health-info/imm-routine-schedule.html.
   Google Scholar
• Government of Saskatchewan. Immuization Services. [ accessed 2017 Oct 2]. www.saskatchewan.ca/residents/health/accessing-health-care-services/immunization-services.
   Google Scholar
• Government of Ontario. Publicly funded immunization schedules for Ontario – December. 2016. [accessed 2017 Oct 3]. http://www.health.gov.on.ca/en/pro/programs/immunization/docs/immunization_schedule.pdf.
   Google Scholar
• Government of New Brunswick. Routine immunization schedule. [ accessed 2017 Oct 3]. http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/CDC/Immunization/RoutineImmunizationSchedule.pdf.
   Google Scholar
• Government of Prince Edward Island. Adult and child immunization in PEI. [ accessed 2017 Oct 2]. www.princeedwardisland.ca/en/information/health-and-wellness/adult-and-child-immunization-pei.
   Google Scholar
• Government of Nova Scotia. School immunization schedule. [ accessed 2017 Oct 3]. https://novascotia.ca/dhw/cdpc/immunization.asp.
   Google Scholar
• Government of Newfoundland and Labrador. Meningococcal disease. [ accessed 2017 Oct 3]. http://www.health.gov.nl.ca/health/publichealth/cdc/pdf/Meningococcal_Vaccine_Fact_Sheet.pdf.
   Google Scholar
• European Centre for Disease Prevention and Control. Vaccine scheduler. [ accessed 2017 Aug 17]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• Government of Western Australia. Targeted campaign against meningococcal W. [ accessed 2017 Nov 29]. https://www.mediastatements.wa.gov.au/Pages/Barnett/2016/12/Targeted-campaign-against-meningococcal-W.aspx.
   Google Scholar
• Victoria State Government Health and Human Services. Meningococcal ACWY Secondary School Vaccine Program in Victoria: Frequently Asked Questions. [ accessed 2017 Aug 17]. http://www.mwsc.vic.edu.au/assets/uploads/2017/05/FAQs-Meningococcal-ACWY-vaccine.pdf.
   Google Scholar
• NSW Government Health. NSW Meningococcal W Response Program. [ accessed 2017 Aug 17]. http://www.health.nsw.gov.au/Infectious/factsheets/Factsheets/meningococcal-w-program.pdf.
   Google Scholar
• Queensland Health. Meningococcal ACWY vaccination program. [ accessed 2017 Aug 17]. https://www.health.qld.gov.au/__data/assets/pdf_file/0022/640147/faq-meningococcal-acwy-program.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease: Surveillance. [ accessed 2017 Nov 29]. https://www.cdc.gov/meningococcal/surveillance/.
   Google Scholar
• Government of Canada. Canadian immunization guide: Part 4 – active vaccines. [ accessed 2017 Nov 29]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html.
   Google Scholar
• Australian Government Department of Health. National immunisation program schedule. [ accessed 2017 Nov 29]. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips.
   Google Scholar
• Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, Ross DA, Watson-Jones D. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. BMC Public Health. 2016;16:172. doi:10.1186/s12889-016-2845-z.
   PubMed Web of Science ®Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, MacNeil J, Markowitz LE, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years–United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29):784–792.
   PubMed Web of Science ®Google Scholar
• Das JK, Salam RA, Arshad A, Lassi ZS, Bhutta ZA. Systematic review and meta-analysis of interventions to improve access and coverage of adolescent immunizations. J Adolesc Health. 2016;59(4S):S40–S48. doi:10.1016/j.jadohealth.2016.07.005.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Teenvaxview. Results for adolescent MenACWY vaccination coverage. [ accessed 2018 Apr 10]. http://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/data-reports/menacwy/index.html.
   Google Scholar
• Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years–united States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(34):685–693.
   PubMed Web of Science ®Google Scholar
• VaxInfo.org. Epidémiologie. Flandre: Couvertures vaccinales élevées en. 2012. [ accessed 2017 Nov 24]. http://www.vaxinfopro.be/spip.php?article824&lang=fr.
   Google Scholar
• Kafetzis DA, Stamboulidis KN, Tzanakaki G, Kourea Kremastinou J, Skevaki CL, Konstantopoulos A, Tsolia M. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin Microbiol Infect. 2007;13(5):550–552. doi:10.1111/j.1469-0691.2007.01704.x.
   PubMed Web of Science ®Google Scholar
• Pascucci MG, Di Gregori V, Frasca G, Rucci P, Finarelli AC, Moschella L, Borrini BM, Cavrini F, Liguori G, Sambri V, et al. Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy. Hum Vaccin Immunother. 2014;10(3):671–676.
   PubMed Web of Science ®Google Scholar
• Direcção-Geral DS. A Saúde dos Portugueses. Boletim Vacinação. No 10. [ accessed 2017 Nov 24]. https://www.dgs.pt/estatisticas-de-saude/estatisticas-de-saude/publicacoes/a-saude-dos-portugueses-perspetiva-2015-pdf.aspx.
   Google Scholar
• Lawrence GL, Wang H, Lahra M, Booy R, Mc IP. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme. Epidemiol Infect. 2016;144(11):2382–2391. doi:10.1017/S0950268816000704.
   PubMed Web of Science ®Google Scholar
• Santé Publique France. Données. Méningocoque C. [ accessed 2017 Nov 24]. http://invs.santepubliquefrance.fr//Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Couverture-vaccinale/Donnees/Meningocoque-C.
   Google Scholar
• MacNeil J, Centers for Disease Control and Prevention. Considerations for use of 2- and 3-dose schedules of MenB-FHbp (Trumenba^®). [ accessed 2017 Mar 21]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-10/meningococcal-05-macneil.pdf..
   Google Scholar
• Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenov I. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration. Pediatr Infect Dis J. 2016;35(1):81–93. doi:10.1097/INF.0000000000000930.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Administering meningococcal vaccines. [ accessed 2017 Nov 29]. https://www.cdc.gov/vaccines/vpd/mening/hcp/administering-vaccine.html.
   Google Scholar
• Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O’Neill RE, York LJ, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatric Infect Dis Soc. 2016;5(2):180–187. doi:10.1093/jpids/piv064.
   PubMed Web of Science ®Google Scholar
• Muse D, Christensen S, Bhuyan P, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O’Neill RE, Harris SL, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673–682. doi:10.1097/INF.0000000000001124.
   PubMed Web of Science ®Google Scholar
• Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden J, Jones TR, York LJ, Jansen KU, O’Neill RE, Harris SL, et al. Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548–554. doi:10.1097/INF.0000000000001072.
   PubMed Web of Science ®Google Scholar
• Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 Suppl):S6–12.
   PubMed Web of Science ®Google Scholar
• Collins L, Dupont L, Nagle D. The impact of educational efforts on first-year university students’ acceptance of meningococcal vaccine. J Am Coll Health. 2003;52(1):41–43. doi:10.1080/07448480309595722.
   PubMed Web of Science ®Google Scholar
• Le Marechal M, Agrinier N, Fressard L, Verger P, Pulcini C. Low uptake of meningococcal C vaccination in France: a cross-sectional nationwide survey of general practitioners’ perceptions, attitudes and practices. Pediatr Infect Dis J. 2017;36(7):e181–e188. doi:10.1097/INF.0000000000001553.
   PubMed Web of Science ®Google Scholar